Jazz Pharmaceuticals reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 per share. The company reported quarterly sales of $1.208 billion which beat the analyst consensus estimate of $1.115 billion.Jazz Pharmaceuticals raised its FY2026 sales guidance from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion.Jazz Pharmaceuticals shares gained 1.4% to $255.00 in pre-market trading.These analysts made changes to their price targets on Jazz Pharmaceuticals following earnings announcement.
Baird analyst Joel Beatty maintained the stock with an Outperform rating and raised the price target from $252 to $280.
Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $260 to $270.
Needham analyst Ami Fadia maintained the stock with a Buy and raised the price target from $282 to $292.
